BSEM
BioStem Technologies, Inc. (NASDAQ)
Healthcare — Biotechnology
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a human connective tissue matrix compromised of amniotic tissue intended for wound covering; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Price History
Fundamentals
| Market Cap | $61.65M |
| P/E Ratio (TTM) | 4.13 |
| Forward P/E | 12.52 |
| EPS (TTM) | $0.88 |
| Dividend Yield | - |
| Profit Margin | -51.28% |
| Revenue Growth | -61.60% |
| ROE | -48.64% |
| Debt/Equity | 10.29 |
| Recommendation | None |
| Analyst Target | $7.00 |
| Analysts | 1 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 44.7 |
| Beta | 0.26 |
| SMA 20 | $3.66 |
| SMA 40 | $3.65 |
| 52-Week High | $10.71 |
| 52-Week Low | $3.01 |
| 50-Day Avg | $3.70 |
| 200-Day Avg | $4.53 |
| Avg Volume | 59.6K |
| Volume | 33.5K |
Performance Analysis
NEUTRALBSEM presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Aug 11, 2026 17:19 UTC
Back to Screener Export Report